Qualigen Inc. Competitors

Pile Dynamics, Inc. (PDI) develops, manufactures and supplies state of the art Quality Assurance and Quality Control systems for the deep foundations industry. With over 50 employees, it is the largest manufacturer of foundation testing equipment in the world. Founded in 1972, PDI was formed to commercialize the Pile Driving Analyzer® (PDA) system of dynamic foundation testing and its associated software now known as CAPWAP®. PDI soon started to increase its line of foundation testing systems. By the late 1970's PDI offered a hand held instrument to detect and count blows during pile driving (the Saximeter). PDI then developed the Hammer Performance Analyzer, the Angle Analyzer and, in the 1980's, the Pile Integrity Tester. The SPT Analyzer joined the PDI line of products in 1995, and the Pile Installation Recorder (for Augered cast-in-place / CFA Piles) in 1998. The Cross-Hole Analyzer for inspecting the quality of drilled shafts was introduced in 2000. Pile Dynamics systems are constantly being updated. The sensors that acquire data for several of its instruments are now wireless, dispensing with cabled connections, and the PDA may be operated remotely through the Internet. PDI's latest development, in partnership with Foundation & Geotechnical Engineering, is the Thermal Integrity Profiler. It embodies a new, temperature based technology for drilled shaft integrity testing. PDI is led by scholars in Dynamic Foundation Testing, who frequently lecture and publish on the subject. Pile Dynamics has representatives worldwide; its products are used in more than 100 countries. Specialties: QA/QC systems for Deep Foundations Pile Integrity Tester PIR for monitoring CFA piles Cross-Hole Analyzer GRLWEAP wave equation analysis of piles software Pile Driving Analyzer® System for Dynamic Load Testing CAPWAP® software Thermal Integrity Profiler

Introducing the TRACER 1000™: The World's First Mobile Mass Spectrometer Redefining Field Detection of explosives and narcotics. Elevate your security protocols with the TRACER 1000™, a revolutionary mobile mass spectrometer that seamlessly combines gold standard lab performance with unmatched field adaptability. The only mass spectrometer based ETD with both ECAC aviation certification and TSA Air Cargo approval, this cutting-edge technology offers unparalleled accuracy and system uptime to ensure precise and dependable detection in any setting. From bustling airports to rigorous border control, dynamic cargo inspections, and high-profile public events, the TRACER 1000™ thrives in the most demanding scenarios. Its portable and user-friendly design caters to the preferences of security professionals worldwide, guaranteeing swift and efficient operation. The TRACER 1000™ stands out as the sole explosives and narcotics trace detector on the market with limitless libraries that can be effortlessly updated to combat the latest threats. Unleash the power of precise detection with the TRACER 1000™, eliminating the disruption caused by false alarms and reducing operational costs. With a focus on delivering accurate results consistently, this advanced system minimizes false positives, ensuring your operations run smoothly without unnecessary interruptions. Investing in the TRACER 1000™ results in superior accuracy and zero downtime, reducing the impact of false alarms and operational disruptions, ultimately saving you time and resources in the long run. Opt for the TRACER 1000™ and experience unmatched accuracy in every application, proving its value day after day through unwavering performance and reliability. Choose excellence with the TRACER 1000™ and elevate your security measures to new heights.

BioMarker Strategies has developed the proprietary SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Our mission is to make personalized medicine more of a reality for these patients. SnapPath® is unique in automating and standardizing functional ex vivo profiling to capture the dynamic and predictive signaling information available only from live solid tumor cells. Our PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatments for solid tumors, because they are based on information available only from live cells. Our business development efforts are directed toward entering into funded collaborations with companies developing targeted therapies for patients with solid tumors. The capabilities of SnapPath® and the Functional Profiles it enables are available for Research Use in preclinical studies in tumorgraft and other model systems, and in early clinical studies to assess pharmacodynamic changes in the solid tumors of individual patients.